OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma
NCT ID: NCT00890877
Last Updated: 2010-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
480 participants
INTERVENTIONAL
2009-04-30
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects
NCT01057927
OC000459 Bronchial Allergen Challenge
NCT01056692
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
NCT01197794
Evaluation of Metabolic Profile of OC000459
NCT02341521
Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594
NCT04002427
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
OC000459 or placebo
Pills, active and/or placebo given twice daily for 17 weeks
2
OC000459 or placebo
Pills, active and/or placebo given twice daily for 17 weeks
3
OC000459 or placebo
Pills, active and/or placebo given twice daily for 17 weeks
4
OC000459 or placebo
Pills, active and/or placebo given twice daily for 17 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OC000459 or placebo
Pills, active and/or placebo given twice daily for 17 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 to 55 years inclusive.
* Non smokers for at least the past 12 months with a pack history of less than 10 pack years.
* Mild to moderate persistent asthma according to GINA4 guidelines for at least 12 months
Exclusion Criteria
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oxagen Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oxagen Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research site
Sofia, , Bulgaria
Research site
Győr, , Hungary
Research site
Warsaw, , Poland
Research site
Bucharest, , Romania
Research site
Moscow, , Russia
Research site
Kiev, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OC000459/012/08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.